General Information

Consumer Behavior and FDA Regulation of Food, Drugs and Tobacco: An FDLI Dialogue

July 24, 2013  | 9 a.m. - 1:30 p.m. | Washington, DC


Drugs, Food, Tobacco



Who Attended:

  • Social scientists and academics
  • Regulatory attorneys
  • Regulatory affairs and R&D staff at drug, tobacco and food companies
  • Public health and consumer advocacy representatives
  • Consultants advising companies on these issues

Program Description

In an open, balanced format, experts discussed and debated the role of consumer behavior research and policy in FDA’s regulation of food, drugs and tobacco and explored the comparative aspects of the three regulatory approaches. FDA assesses the safety and effectiveness of products subject to its jurisdiction (or, for tobacco, that such products are appropriate for the public health).  The role of consumer behavior and research in helping FDA achieve these mandates is not always clear, but always important, making this an ideal subject for an FDLI Dialogue. Case studies and discussion addressed the key role consumer research plays in REMS programs, Rx to OTC switches, food labeling and modified risk tobacco products. Participants engaged with lead discussants on questions related to consumer perception, use patterns, behavioral research models and methods, and the potential commercial and regulatory impact of this research. 

More About FDLI Dialogues

FDLI Dialogues are convened for stakeholders to discuss evolving policy in emerging areas of food and drug law. With the focus on audience participation and discussion, these are not typical panel- and speaker-focused educational programs. Dialogues are typically half-day programs, often offered with the option to participate in-person or by teleconference.